OJEMDA 25 mg/ml, powder for oral suspension bottle, 30 ml
Active ingredients: TOVORAFÉNIB
Commercialized according to BDPMDispensing in France: Prescription only
Powder for oral suspensionbottle, 30 mlorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- OJEMDA 25 mg/mL, poudre pour suspension buvable
- Pharmaceutical form
- poudre pour suspension buvable
- Route of administration
- orale
- Presentation description
- 1 flacon(s) en verre de 30 ml + 1 adaptateur pour flacon + 1 seringue pour administration orale
- Marketing authorisation holder
- IPSEN PHARMA
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 2 Sept 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
64661975CIP73033754CIP133400930337547Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TOVORAFÉNIBpoudre | 25 mg · 1 mL de suspension reconstituée | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.